 |
|
Super Sessions
Biotech Investing: What Has and Has Not Worked in the Past Two Decades?Sunday, May 6, 2007 The panelists, with more than two decades of investing in biotechnology each, will reflect on business models that have and have not worked for investors and companies alike. A sampling of the questions to be discussed: • Are all “products” created equal from an investor and return viewpoint? Small molecules, proteins, (bio) information, targets, platforms? Which have done the best and worst? Chair:
Speakers:
Global challenges and Opportunities for the Bio-Economy: the European ContributionSunday, May 6, 2007 Ambassador John Bruton is a former Irish Prime Minister (Taoiseach). As Ambassador, Mr. Bruton is also Head of the EU Commission’s Washington Delegation. The European Union and the United States are the two largest economies in the world. In 2007, the European Union celebrates its 50th birthday. In these 50 years, the EU has created a single market where goods, people, services and capital can move freely. The EU creates opportunities for the biotechnology industry by modernising its regulation of bio-pharmaceuticals to create legal certainty for newly emerging products. Its funding programmes provide over US $ 1 billion annually to tackle challenges such global diseases and developing renewable energy resources. Speaker:
Pandemic Influenza: Are we Prepared and How are we Getting There?Monday, May 7, 2007 Over the past five years, the biopharma industry has enjoyed, in financial terms, overwhelming governmental support due to the focus on biodefense and biosecurity. However, the SARS and anthrax crisis, although limited in their outreach, revealed how poorly governments, research institutes and large corporations were prepared to face the potentially enormous dangers—including economic losses—posed by these new types of outbreak. Precious time was lost before key stakeholders were able to coordinate their efforts, ultimately under the leadership of WHO for the SARS episode. Should a true pandemic of natural or man-made origin strike the planet, will society, science and industry remain ill-prepared, putting millions of lives at risk? Chair:
Speaker:
Burrill Report - Biotechnology State of the IndustryMonday, May 7, 2007 The year 2006 was an exciting one for the biotech industry with the capital markets dramatically improved, driven by powerful new genomics and technologies that are changing both drug discovery and development . . . and leading us toward personalized medicine, more predictability and, ultimately, preventative medicine (the treatment of wellness). Regulatory development (especially in this post-Vioxx world), product approvals, product success in the marketplace, and mergers/acquisitions have changed the landscape for biotech dramatically. G. Steven Burrill's annual "state of the industry" analysis has been an important part of the biotech industry's view of itself over the last 21 years. Biotech 2007, a perspective on the industry's global transformation, will be the focus of this talk. Speaker:
Ministerial SeminarTuesday, May 8, 2007 The 2007 Ministerial Seminar will deliver firsthand information about the latest initiatives to support biotechnology innovation in key strategic regions representing both emerging and established biotechnology markets. Federal level ministers of science & technology, trade, and/or economics will focus on the advancement of stable innovation systems through predictable funding, intellectual property and data protection frameworks, and regulation and the climate for biotechnology commercialization in health care, food & agriculture, and industrial & environmental biotech. Speakers:
Ernst & Young 2007 Global Biotechnology ReportTuesday, May 8, 2007 The biotechnology industry’s performance remains strong, with the U.S. industry edging closer to aggregate profitability, and investors increasingly drawn to the sector. The potential of biofuels to address pressing economic and environmental issues, for instance, is attracting capital and supportive public policy. M&A valuations have soared, as big pharma and biotech buyers are willing to pay for the right strategic assets. Financing remains robust, with large amounts raised across the world, and European IPOs besting 2005’s exceptional performance. But as the industry matures, new challenges are emerging. Many companies are entering unfamiliar territory as they deal with regulatory challenges, product launches, an increasingly competitive deal environment, and disappointing IPO valuations. This panel session will highlight trends and challenges from Ernst & Young's 2007 biotechnology report, with comprehensive global data on financial performance, financing, deals, products, pipeline, and regulatory trends. Representing Ernst & Young will be:
Other panelists include:
Improving Biotechnology Industry Access to Underserved PopulationsWednesday, May 9, 2007 This symposium will address biotechnology industry efforts to improve access to innovative treatments and encourage participation of minority communities in the biotechnology endeavor. For the biotechnology industry to fulfill its promise of conquering diseases, addressing hunger, and improving quality of life for everyone, all communities must be active participants in the discovery, trade and entrepreneurship of this industry. This session, sponsored by Genentech, marks a continuation of a dialogue that began at the BIO 2005 meeting. This year’s session will feature industry leaders as well as well as minority community representatives dedicated to promoting diversity in biotechnology. Who should attend: This is a general session designed for all biotechnology industry leaders, researchers/scientists, minority community leaders, entrepreneurs, healthcare professionals and public officials with an interest in working with minority and underserved communities. Moderator:
Panelists:
|
   |
